abs175.txt	the	phase	4	abound	70+	trial	assessed	safety	and	efficacy	ofnab-paclitaxel/carboplatin	continuously	or	with	a	1-week	break	between	cycles	inelderly	patients	advanced	non-small	cell	lung	cancer	(nsclc)		patients≥70	years	locally	advanced/metastatic	nsclc	were	randomized	1	tofirst-line	nab-paclitaxel	days	8	15	plus	carboplatin	day	of	21-day	cycle(21d)	same	nab-paclitaxel/carboplatin	regimen	betweencycles	(21d	+	28d)	primary	endpoint	was	percentage	patientswith	grade	≥	2	peripheral	neuropathy	(pn)	3	myelosuppression	otherkey	endpoints	included	progression-free	survival	(pfs)	overall	(os)	response	rate	(orr)	total	143	(71	to21d	72	to	21d	break)	pn	orgrade	similar	arms	(76	5and	77	1%	p	=	0	9258)	treatment	exposure	lower	in	arm	compared	withthe	median	os	16	months	[hazard	ratio	(hr)	95%	ci	44-1	19	1966]	pfs	6	7	(hr	48	ci0	30-0	76	<	0019)	orr	23	9	40	3%	(risk	68	ci1	02-2	78	0376)	respectively	summary	significantly	improved	butdid	not	reduce	3myelosuppression	findings	support	results	prior	subsetanalyses	on	first-line
